← Russell 3000 cross-section

MDT Medtronic plc

Trailing twelve months to 2026-04-24 · as filed 2026-06-18, not restated
Healthcare

Scale

Market cap
$116.7bn
Revenue TTM
$36.4bn
Net income TTM
$4.8bn
Free cash flow
$5.4bn
Composite score
66.8
Sector rank
#102

Valuation

P / E
24.3
EV / EBITDA
11.6
EV / sales
3.0
FCF yield
4.65%
Earnings yield vs 10-yr
-0.62pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
13.2%
EBITDA margin
25.9%
ROE
9.7%
ROIC
15.4%
Revenue growth
8.4%

Insider activity, last 90 days

Net open-market
$-0.59m
Buyers
0
Sellers
2

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

(3) The charges primarily include business combination costs, changes in fair value of contingent consideration, exit of business-related charges, and gains related to certain business or asset sales. (3) The charges primarily include business combination costs, changes in fair value of contingent consideration, exit of business-related charges, and gains related to certain business or asset sales. As of January 23, 2026, the Company had 6 facilities and approximately 1,200 employees in Israel and the business of the Company represented less than 1% of the Company's consolidated revenues and assets. …Medtronic plc, 10-Q, period ended 2026-01-23, filed 2026-02-24

Read the full passage →